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ED I T OR I A L
To find glomerulonephritis 
you have to look for it
C.A. Stegeman 
Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, 
Groningen, the Netherlands, email: c.a.stegeman@umcg.nl 
Anti-neutrophil cytoplasmic antibodies (ANCA) associated 
small vessel vasculitis is a systemic auto-immune 
disease with widespread and highly variable clinical 
manifestations. Renal involvement, usually in the form 
of necrotising crescentic glomerulonephritis (pure 
necrotising renal vasculitis without glomerulonephritis 
is very rare), is frequently one of the manifestations 
of the disease and is encountered in the majority of 
patients at diagnosis.1 The severity of renal involvement 
has both therapeutic and prognostic consequences. 
Most management guidelines determine the intensity 
of immunosuppressive therapy on the severity of vital 
organ dysfunction, which in many patients is defined by 
the level of renal failure.1,2 In addition, the level of renal 
failure at diagnosis and especially the failure to regain 
renal function during induction therapy is associated with 
a worse outcome and high mortality.3,4 So assessment 
of the presence and severity of renal involvement in 
ANCA-associated vasculitis is mandatory and an essential 
part of patient care and the selection of appropriate 
treatment.
The diagnosis of ANCA-associated vasculitis has been 
made more straightforward by the discovery of the high 
sensitivity and specificity of autoantibodies directed against 
proteinase-3 and myeloperoxidase.5,6 Reliable assays to 
detect these antibodies are available. Also awareness of 
these diseases has probably increased over the last decades. 
It is conceivable that the diagnosis of ANCA-associated 
vasculitis is made more timely and that the proportion of 
patients with severe organ dysfunction including severe 
renal failure is declining and patients are diagnosed in an 
earlier and more limited phase of the disease. This view is 
illustrated by the finding of Houben et al. described in this 
issue of the journal that in 109 patients diagnosed with 
ANCA-associated vasculitis the median serum creatinine 
at diagnosis was low despite renal involvement in 61% of 
the patients at diagnosis.7 
Most patients with ANCA-associated vasculitis will 
not present with visual or other overt signs of renal 
involvement: macroscopic haematuria is usually absent 
as one of the presenting symptoms and proteinuria 
is frequently mild, not leading to the clinical signs of 
nephrotic syndrome. This is also nicely illustrated by 
the paper by Houben as only 21 of the patients from 
their cohort were diagnosed by the renal department. 
This means that patients present with combinations 
of other signs and symptoms and are referred to other 
disciplines. Renal involvement, therefore, has to be actively 
investigated once the diagnosis of ANCA-associated 
vasculitis is suspected. This means that in every patient 
in whom the diagnosis of ANCA-associated vasculitis 
is seriously considered, assessment of renal function 
(serum creatinine, estimated glomerular filtration rate 
(eGFR), 24-hour urine creatinine clearance) and urinalysis 
(erythrocyturia and if present urinary microscopy for 
glomerular erythrocyturia and/or erythrocyte casts, 
proteinuria) should be performed.1,2 As Houben et al. 
describe, it is worrying that renal involvement is not 
actively investigated in a proportion of patients with 
suspected or confirmed ANCA-associated vasculitis, not 
even in the weeks and months following the diagnosis. 
The 19 of 109 patients (22% in patients not diagnosed in 
the renal department) with ANCA-associated vasculitis not 
screened for renal involvement in their study had a lower 
serum creatinine (median 70 µmol/l, IQR 56-89 µmol/l) 
at diagnosis, which may have led to the misconception 
that a serum creatinine in the ‘normal’ range effectively 
excludes the presence of renal involvement. In addition, we 
have to repeat the message that a so called ‘normal’ serum 
creatinine is not the equivalent of normal renal function. 
Especially in an older population (mean age at diagnosis 
62 ± 14 years in the cohort described by Houben) and 
in persons with a systemic inflammatory illness lasting 
for some time and leading to muscle wasting, serum 
creatinine levels can be deceptively low despite significant 
renal impairment. 
As renal involvement is usually seen as a sign of more 
severe disease in ANCA-associated vasculitis, the failure to 
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recognise renal involvement early may lead to insufficient 
treatment of patients, which is suggested by the fact that 
cyclophosphamide induction therapy was given to only 
37% of those not screened for renal involvement. Also the 
fact that, despite a lower serum creatinine at diagnosis, 
at three years of follow-up renal function as estimated by 
eGFR was clearly lower in patients who did not receive 
cyclophosphamide induction compared with those who 
did may point in that direction. Finally, it should be 
highlighted that even in the minority of patients with 
documented absence of renal involvement at diagnosis, 
during follow-up renal involvement may develop. In a 
recent series from our centre this was the case in 21%, 
while at least half of all relapses in patients with renal 
involvement at diagnosis show renewed renal activity.4 This 
means that screening for renal involvement is not only 
mandatory in the diagnostic phase, but also is an essential 
part of assessment for disease activity during follow-up. 
This is essential to all of us who diagnose and treat patients 
with these diseases. To paraphrase one of the rules from 
‘The House of God’ by Samuel Shem: you won’t find renal 
small vessel vasculitis if you don’t do a urinary sediment. 
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